Masupirdine is an investigational new drug that is being evaluated for the treatment of agitation in Alzheimer's dementia.[1] It is a selective 5-HT6 receptor antagonist.[2]

Masupirdine
Identifiers
  • 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H24BrN3O3S
Molar mass478.41 g·mol−1
3D model (JSmol)
  • CN1CCN(CC1)CC2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br
  • InChI=1S/C21H24BrN3O3S/c1-23-9-11-24(12-10-23)14-16-15-25(20-8-7-17(28-2)13-18(16)20)29(26,27)21-6-4-3-5-19(21)22/h3-8,13,15H,9-12,14H2,1-2H3
  • Key:GWCYPEHWIZXYFZ-UHFFFAOYSA-N

References

edit
  1. ^ "Masupirdine - Suven Life Sciences". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Nirogi R, Jayarajan P, Shinde A, Mohammed AR, Grandhi VR, Benade V, et al. (February 2023). "Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders". Biomolecules. 13 (2): 309. doi:10.3390/biom13020309. PMC 9953539. PMID 36830678.